NDA 008316 · Sanofi Aventis US
Primaquine
Primaquine Phosphate · Oral
Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1952
Jan 23, 1952
Approved uses
1
Original approval plus efficacy supplements
Registered trials
124
31 Phase 3, 7 recruiting
FAERS reports
87
76 serious, 6 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 11, 2026.
INDICATIONS AND USAGE Primaquine phosphate Tablets are indicated for the radical cure (prevention of relapse) of vivax malaria.
Mechanism: Mechanism of Action Primaquine phosphate is an 8-aminoquinoline antimalarial drug. The mechanism of action has not been fully established. The major assumptions are an inhibition of the mitochondrial system of dormant parasites, and an oxidative stress generated through reactive metabolites in infected cells. In humans, primaquine phosphate activity is probably related to hydroxylated metabolites generated intrahepatically by CYP2D6.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 23, 1952 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- PRIMAQUINE · PRIMAQUINE PHOSPHATE EQ 15MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Primaquine" as an intervention, any sponsor and status, largest first.
- Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic RepublicPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT03783299 · 39,968 participants · Start Nov 28, 2017 · Primary completion Nov 30, 2018
Drug: Artemether-lumefantrine; Primaquine Phosphate · For: Plasmodium Falciparum Malaria
Sites: Vientiane, Laos
- Effectiveness of Mass Drug Administration for Reducing Seasonal Malaria Transmission in ZanzibarPivotal-lookingCompleted
Ulrika MorrisAcademic, hospital or other
NCT02721186 · 22,500 participants · Start Apr 30, 2016 · Primary completion Dec 31, 2016
Drug: MDA with DHAp and SLD Primaquine · For: Malaria; Plasmodium Infections
Sites: Mwanakwerekwe, Tanzania
- MDA and Targeted Control Against Plasmodium Carriage in the SahelPivotal-lookingActive, not recruiting
Institut de Recherche pour le DeveloppementGovernment (non-federal)
NCT07281443 · 18,000 participants (planned) · Start Sep 23, 2024 · Primary completion Dec 2026
Drug: MDA with DHAp and SLD Primaquine · For: Malaria, Falciparum; Malaria, Asymptomatic Parasitaemia
Sites: Kedougou, Senegal
- Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward Elimination ActivitiesPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT04864444 · 10,715 participants · Start Jun 19, 2021 · Primary completion Dec 31, 2022
Drug: Dihydroartemisinin-piperaquine; Primaquine · For: Malaria,Falciparum; Malaria
Sites: Tambacounda, Senegal
- Mass Vaccine and Drug Administration, BangladeshPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT06068530 · 10,000 participants (planned) · Start Feb 15, 2025 · Primary completion Feb 1, 2028
Drug: DHA/piperaquine and a SLD-PQ; Study vaccine R21/Matrix-M™ · For: Plasmodium Falciparum Malaria
Sites: Bāndarban, Bangladesh; Lāma, Bangladesh
- Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of GhanaPivotal-lookingRecruiting
Noguchi Memorial Institute for Medical ResearchAcademic, hospital or other
NCT07389057 · 9,000 participants (planned) · Start Nov 1, 2023 · Primary completion Nov 30, 2026
Drug: DHAP; Single low dose PQ · For: Malaria Asymptomatic Parasitaemia; Malaria Falciparum; Malaria Infection and 1 more
Sites: Accra, Ghana
- Targeted Chemo-elimination (TCE) of MalariaPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT01872702 · 8,000 participants · Start Apr 2013 · Primary completion Jul 2017
Drug: malaria elimination using DP and low-dose primaquine · For: Plasmodium Falciparum Malaria
Sites: Rangoon, Burma; Pailin, Cambodia; Savannakhet, Laos · 5 sites in all
- FocaL Mass Drug Administration for Vivax Malaria EliminationPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT05690841 · 7,530 participants (planned) · Start Oct 14, 2024 · Primary completion May 1, 2027
Drug: Focal Mass Drug Administration (fMDA) · For: Plasmodium Vivax Malaria; Malaria
Sites: Iquitos, Peru
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- methaemoglobinaemia20
- drug ineffective13
- drug interaction12
- pyrexia10
- cyanosis8
- plasmodium vivax infection7
- chromaturia6
- dyspnoea6
- off label use6
- drug eruption5
- headache5
- hyponatraemia4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 1 |
| 2010 | 1 |
| 2012 | 3 |
| 2013 | 7 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 7 |
| 2020 | 1 |
| 2021 | 33 |
| 2022 | 9 |
| 2023 | 1 |
| 2026 | 5 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Primaquine (Primaquine Phosphate)
2024 spending
$27K
Beneficiaries
336
470 claims
Per beneficiary
$79
$1.41 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $13,854 |
| 2021 | $13,434 |
| 2022 | $18,535 |
| 2023 | $26,191 |
| 2024 | $26,597 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of treatment regimens for Pneumocystis jirovecii pneumonia in people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Hatzl S, Posch F, Scholz L, et al. · Clin Microbiol Infect 2025 · Systematic Review, Comparative Study
- Malaria: prevention in travellers.
Croft AM · BMJ Clin Evid 2010 · Systematic Review
- Malaria: prevention in travellers.
Croft AM · BMJ Clin Evid 2007 · Systematic Review
- Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.
Rajasekhar M, Simpson JA, Ley B, et al. · Lancet Infect Dis 2024 · Systematic Review, Meta-Analysis
- Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.
Commons RJ, Rajasekhar M, Edler P, et al. · Lancet Infect Dis 2024 · Systematic Review, Meta-Analysis
- Safety and efficacy of single-dose primaquine to interrupt Plasmodium falciparum malaria transmission in children compared with adults: a systematic review and individual patient data meta-analysis.
Yilma D, Stepniewska K, Bousema T, et al. · Lancet Infect Dis 2025 · Systematic Review, Meta-Analysis
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.